Current Neuroblastoma News and Events | Page 3

Current Neuroblastoma News and Events, Neuroblastoma News Articles.
Sort By: Most Relevant | Most Viewed
Page 3 of 9 | 325 Results
MDC researchers discover new regulatory mechanism of important protein
Protein kinase A (PKA) is an important signaling enzyme that is found throughout the body and is involved in many cellular processes. It was thought to have been comprehensively studied, but scientists at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) have now discovered a new layer of PKA regulation and published their findings in Nature Communications. (2016-10-07)

Nuclear protein causes neuroblastoma to become more aggressive
Aggressive forms of neuroblastoma contain a specific protein in their cells' nuclei that is not found in the nuclei of more benign forms of the cancer, and the discovery, made through research from the University of Rochester Medical Center, could lead to new forms of targeted therapy. (2016-10-06)

Accumulation of a product of cell metabolism found to be linked with kidney tumor growth
Researchers funded by the Medical Research Council have shown that when the metabolite fumarate accumulates in a hereditary form of renal cancer it leads to an epigenetic reprogramming that drives cancer. The tumor growth mechanism seen here could be similar in other cancers, such as lung and bowel cancer, where the enzyme that breaks down fumarate is not present or not fully functional. (2016-08-31)

Researchers at Nationwide Children's Hospital describe new type of cancer therapy
A study conducted at Nationwide Children's Hospital has found that a new chemotherapy is effective against both pediatric and adult cancers, and that it allows other chemotherapies to more readily reach their targets. (2016-07-27)

Loss of a microRNA family, let-7, found key in neuroblastoma
A study led by researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, finds that a microRNA called let-7 plays a central role in curbing neuroblastoma and could focus efforts to find a targeted, nontoxic alternative to chemotherapy. (2016-07-07)

Doctors unleash new weapon to fight pediatric neuroblastoma
After the first year of receiving the novel treatment combination, more than half of children with relapsed neuroblastoma saw either a complete or partial remission -- a 53 percent response rate compared to the typical 10 to 12 percent response rate. (2016-06-06)

Dual stem-cell transplant improves outlook for children with high-risk neuroblastoma
Children with high-risk neuroblastoma whose treatment included two autologous stem-cell transplants were more likely to be free of cancer three years later than patients who underwent a single transplant, a Phase 3 clinical trial has found, according to research presented at the annual meeting of the American Society of Clinical Oncology. The tandem transplant technique produced even better results when followed by treatment with immunotherapy agents. (2016-06-05)

St. Jude Children's Research Hospital research being presented at ASCO Annual Meeting
St. Jude Children's Research Hospital research related to survivorship and the pediatric solid tumors neuroblastoma, adrenocortical carcinoma and nasopharyngeal carcinoma will be presented at the 2016 American Society of Clinical Oncology Annual Meeting. The five-day event begins June 3 in Chicago. (2016-06-03)

Investigational immunotherapy drug shrinks tumors in high-risk neuroblastoma patients
St. Jude Children's Research Hospital investigators report promising preliminary results at the annual meeting of ASCO for an experimental monoclonal antibody when combined with chemotherapy for newly diagnosed patients. (2016-06-03)

Damon Runyon Foundation selects new recipients of Physician-Scientist Training Award
To help increase the number of physician-scientists, the Damon Runyon Cancer Research Foundation has created the new Damon Runyon Physician-Scientist Training Award, which provides physicians who have earned an M.D. degree and completed clinical specialty fellowship training the opportunity to gain the research experience they need to become leaders in translational and clinical research. Damon Runyon announced that five scientists with novel approaches to fighting cancer have been named the 2016 recipients of the award. (2016-05-23)

For some cancers, risk lower among kids of non-US-born Hispanic mothers
The children of Hispanic mothers not born in the United States appeared to have a lower risk for some types of childhood cancers, according to an article published online by JAMA Pediatrics. (2016-04-25)

The Lancet Oncology: Study suggests most female childhood cancer survivors have good chance of becoming pregnant
For women who have survived childhood cancer, the impact of modern chemotherapy regimens on the likelihood of becoming pregnant is generally small, and most have a good chance of conceiving, according to one of the largest studies of its kind published in The Lancet Oncology. In contrast, male survivors of childhood cancer are significantly less likely to have children, especially if they are treated with chemotherapy regimens containing high doses of commonly used alkylating drugs and cisplatin. (2016-03-22)

VCU scientists work to bring about a new treatment for rare childhood cancer
Neuroblastoma is a rare cancer that develops in very early forms of nerve cells in the embryo or fetus, and it accounts for the most pediatric deaths for any tumor outside of the brain. The most lethal form of this tumor is often associated with amplification of the gene MYCN, and now VCU scientists may have developed a combination therapy that uses this gene to kill the cancer, instead of making it grow. (2016-03-07)

Robert Seeger, MD, selected for award from Pediatric Blood and Marrow Transplant Consortium
Robert Seeger, MD, division head for Basic and Translational Research of the Center for Cancer and Blood Diseases at Children's Hospital Los Angeles has been selected for the 2016 Lifetime Achievement Award from the Pediatric Blood and Marrow Transplant Consortium. (2016-02-23)

Unique next generation sequencing-based panel designed for pediatric cancer research
Children's Hospital Los Angeles and Thermo Fisher Scientific have agreed to develop a next-generation sequencing (NGS)-based panel designed specifically for pediatric cancer research. The assay would be CHLA's first NGS panel designed to target biomarkers associated with childhood cancers. (2016-02-18)

Breakthrough in generating embryonic cells that are critical for human health
Critical for human development and health, neural crest cells arise early in the development of vertebrates. They migrate extensively inside the embryo, and differentiate to give rise to a wide array of diverse derivatives. Accessing these cells, however, is difficult. Work done by a research team led by a UC Riverside biomedical scientist now provides a fast, simple and cost-effective method to generate neural crest cells, facilitating research in basic sciences and clinical applications alike. (2016-02-03)

Basic research led to first FDA-approved immunotherapy for pediatric cancer
Researchers at Children's Hospital Los Angeles have shown that an immunotherapy that until now has only been available to patients enrolled in research studies, is equivalent to the product that has been manufactured for commercial use and can be made available to all patients. The data, published in the journal Cancer Chemotherapy and Pharmacology on Jan. 20, was pivotal to the FDA approval of the first immunotherapy for the treatment of a pediatric cancer. (2016-01-27)

Gene often lost in childhood cancer crucial in cells' life or death decision
A gene that is often lost in childhood cancer plays an important role in the decision between life and death of certain cells, according to a new study published in the journal Developmental Cell. Researchers at Karolinska Institutet and Ludwig Cancer Research in Sweden have discovered the process by which that gene, KIF1B-β, kills cells and thereby suppresses tumour development. (2016-01-25)

New drug may overcome treatment resistance in a high-risk children's cancer
Pediatric oncologists from The Children's Hospital of Philadelphia have reported their latest results in devising new treatments for stubbornly deadly forms of the childhood cancer neuroblastoma. The 'unparalleled' strength of an ALK inhibitor in their preclinical studies, say the researchers, justifies fast-tracking the drug into pediatric clinical trials this year. (2016-01-06)

Girl's dream to be a veterinarian prompts $30,000 donation to TGen canine cancer studies
An 8-year-old girl's dream of becoming a veterinarian, cut short by a deadly tumor, is the driving force behind a $30,000 donation to support research of dogs and children with cancer at the Translational Genomics Research Institute (TGen). Brooke Hester waged a valiant battle with cancer for nearly five years before succumbing to her disease in June. She had been part of an innovative study for children with rare cancers conducted by TGen. (2015-12-22)

American Cancer Society awards 'Shine A Light' Funds to neuroblastoma researcher
The American Cancer Society has selected Dr. Andras Heczey of Texas Children's Cancer Center as the recipient of a four-year grant funded by TODAY Show viewers through its 'Shine A Light' campaign. (2015-12-16)

Grant to CHOP funds personalized treatments for children with neuroblastoma
A new $1.5 million grant to The Children's Hospital of Philadelphia from Alex's Lemonade Stand Foundation supports an innovative approach to treating relapsed or refractory neuroblastoma, a high-risk childhood cancer. CHOP researchers are launching a pediatric clinical trial with a dynamic design allowing them to quickly incorporate new treatments by matching gene changes in an individual patient's tumor to available drugs. (2015-12-10)

Change in a single DNA base drives a childhood cancer
Pediatric oncology researchers have pinpointed a crucial change in a single DNA base that both predisposes children to an aggressive form of the childhood cancer neuroblastoma and makes the disease progress once tumors form. The gene change results in a 'super enhancer' that drives the cancer. (2015-11-11)

Environmental factors may contribute to the development of some childhood cancers
Environmental factors may be a contributory cause in the development of some childhood cancers, leading scientists have revealed. (2015-11-09)

A way to target the Achilles heel of neuroblastoma
Australian scientists have identified a critical molecular 'feedback loop' that helps initiate and drive neuroblastoma, a cancer of the nervous system in children that is triggered in embryonal nerve cells. The research team have also identified an experimental drug, currently in clinical trials for adult cancer, with the potential to interrupt the loop and halt tumor progression. (2015-11-04)

Cancer-driving signals cause high-risk neuroblastoma
Researchers have discovered details of the abnormal molecular signals and biological events that drive a high-risk form of the childhood cancer neuroblastoma. Having investigated a signaling network involving three cancer-causing genes, the scientists aim to use these findings to develop more effective targeted treatments. (2015-10-15)

Targeted chemotherapy shows early signs of slowing tumor growth with less toxicity
Surviving neuroblastoma as a child can come with just as many challenges as the cancer itself, mainly because of the toxic effects of chemotherapy. But a team of surgeons is in the nascent stages of developing a more targeted method of treating neuroblastoma patients with chemotherapy and lower toxicity. (2015-10-06)

Cancer doesn't sleep: Myc oncogene disrupts clock and metabolism in cancer cells
Myc is a cancer-causing gene responsible for disrupting the normal 24-hour internal rhythm and metabolic pathways in cancer cells. The researchers found that MYC protein may affect circadian rhythm and metabolism by promiscuously binding to promoter regions in key genes for maintaining these daily cycles. (2015-09-17)

Childhood cancer cells drain immune system's batteries
Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for the body's immune cells, leaving them too physically drained to fight the disease, according to new research published in the journal Cancer Research today. (2015-08-01)

UofL offers vaccine trial for children with relapsed tumors at Kosair Children's Hospital
Children with relapsed tumors and their parents are finding hope in a Phase I research study led by Kenneth G. Lucas, M.D., at the University of Louisville who is making progress in developing a vaccine that one day could possibly prevent recurrence of some cancers. (2015-07-16)

New drug for neuroblastoma shows promise in phase I study
Researchers at Spectrum Health Helen DeVos Children's Hospital have completed the first clinical trial of a new treatment for children suffering from neuroblastoma. In a clinical trial led by Giselle Sholler, M.D., and the Neuroblastoma and Medulloblastoma Translational Research Consortium, DFMO, an investigational agent, showed minimal side effects with long-term survival of three patients. This is the first clinical study of an oral dosing form of DFMO in any pediatric population. (2015-07-01)

Pinpointing mutations in a relapsed children's cancer may lead to improved treatments
Researchers studying the pediatric cancer neuroblastoma have detailed how cancer-driving mutations evolve during chemotherapy, and they hope to exploit this knowledge to design better treatments for children. (2015-06-29)

How the tumor microenvironment contributes to drug-resistant neuroblastoma
Researchers at Children's Hospital Los Angeles have made an important step toward finding a target in the fight against drug-resistant neuroblastoma, the most common solid malignancy found, outside of the skull, in children. (2015-05-13)

UM biologist advances cancer research with new data analysis techniques
Patience and persistence are beginning to pay off for University of Montana Professor Mark Grimes, whose research about the behavior of cell proteins in childhood cancer recently was published by the PLOS Computational Biology. (2015-05-08)

Maternal stress increases development of fetal neuroblastoma in animal model
While genetics play a substantial role in development of neuroblastoma, scientists say that something else is in play that elevates the risk: stress. Researchers have shown in mice genetically predisposed to develop neuroblastoma that maternal stress can push onset of the cancer. (2015-04-21)

A common nerve protein elevated in aggressive neuroblastomas
A protein produced by nerve cells appears to be elevated in the blood of those with an aggressive form of neuroblastoma. The finding could potentially lead to a prognostic test for the disease or be used to monitor its progress. (2015-04-20)

Nanoparticles may exploit tumor weaknesses to selectively attack cancers
Delving into the world of the extremely small, researchers are exploring how biodegradable nanoparticles can precisely deliver anticancer drugs to attack neuroblastoma, an often-deadly children's cancer. The approach may represent a new fourth arm of targeted pediatric cancer treatment, joining T-cell immunotherapy, radioactive isotopes and kinase inhibitors that disrupt cancer-driving signaling. (2015-04-02)

Microenvironment provides growth factor for metastasis
When a person has cancer that spreads to the bone and bone marrow, the tissue becomes increasingly fragile, often leading to increased bone resorption. In a surprising discovery, investigators at Children's Hospital Los Angeles found that when neuroblastoma cells metastasize to the bone, there initially occurs an increase in bone deposition, not resorption. They also determined that this process is driven by a chemical messenger called VEGFA. (2015-03-17)

A novel immunotherapy technique to treat patients with osteosarcoma and neuroblastoma
A novel phase 1 clinical trial that leverages T-cell immunotherapy is now under way at Karmanos Cancer Institute in Detroit and Memorial Sloan-Kettering Cancer Center in New York City, bringing new hope to children and young adults with osteosarcoma and neuroblastoma. This new clinical trial is being funded by charity partners Solving Kids' Cancer and Fishin' For The Cure. (2015-02-26)

A new weapon in the fight against cancer
New research from Concordia University confirms that a tool for keeping the most common forms of cancer at bay could be in your gut. (2015-02-17)

Page 3 of 9 | 325 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.